 Ocuphire Pharma Inc NASDAQ: OCUP has screened the first patient in Phase 2 ZETA-1 trial evaluating APX3330 in non-proliferative diabetic retinopathy NPDR and mild proliferative diabetic retinopathy mild PDR. Effects on diabetic macular edema will be explored as a secondary outcome. 